Long-term survival and cost analysis of an annual Barrett's surveillance programme

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 4, 2010, Pages 399-403

  Roberts, Keith J ^a   Harper, Edward ^b   Alderson, Derek ^c   Hallissey, Mike ^c  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

^c Renal Institute of Birmingham   (United Kingdom)

Author keywords

Barrett's oesophagus; Cost analysis; Endoscopic surveillance; Oesophageal adenocarcinoma

Indexed keywords

CISPLATIN; DEXAMETHASONE; EPIRUBICIN; FLUOROURACIL; ONDANSETRON;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER STAGING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIGESTIVE TRACT ENDOSCOPY; DYSPLASIA; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL DYSPLASIA; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SURVIVAL TIME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; COSTS AND COST ANALYSIS; DISEASE PROGRESSION; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; SURVIVORS; TREATMENT OUTCOME;

EID: 77949460764     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328331fc9c     Document Type: Article

References (26)

1. Visbal AL, Allen MS, Miller DL, Deschamps C, Trastek VF, Pairolero PC. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2001; 71:1803-1808.
2. Shaheen NJ. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2005; 128:1554-1566.
3. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356:2079-2085.
4. Loft DE, Alderson D, Heading RC. Screening and surveillance in columnarlined oeosphagus. Br Soc Gastroenterol Guidel 2005:28-32.
5. Wang K, Wongkeesong M, Buttar NS. American gastroenterological association medical position statement: role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 2005; 128:1468-1470.
6. Macdonald CE,Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000; 321:1252-1255.
7. Aldulaimi DM, Cox M, Nwokolo CU, Loft DE. Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur J Gastroenterol Hepatol 2005; 17:943-950.
8. Pohl H, Aschenbeck J, Drossel R, Schroder A, Mayr M, Koch M, et al. Endoscopy in Barrett's oesophagus: adherence to standards and neoplasia detection in the community practice versus hospital setting. J Intern Med 2008; 264:370-378.
9. Von Rahden BH, Stein HJ,Weber A, Vieth M, Stolte M, Rosch T, et al. Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database. Dis Esophagus 2008; 21:685-689.
10. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138:176-186.
11. Somerville M, Garside R, Pitt M, Stein K. Surveillance of Barrett's oesophagus: is it worthwhile? Eur J Cancer 2008; 44:588-599.
12. Inadomi JM. Surveillance in Barrett's esophagus: a failed premise. Keio J Med 2009; 58:12-18.
13. Moayyedi P. Economic aspects of surveillance. Br Soc Gastroenterol Guidel 2005:37-39.
14. DeMeester SR. New options for the therapy of Barrett's high-grade dysplasia and intramucosal adenocarcinoma: endoscopic mucosal resection and ablation versus vagal-sparing esophagectomy. Ann Thorac Surg 2008; 85:S747-S750.
15. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359:1727-1733.
16. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36-46.
17. Ramus JR, Gatenby PA, Caygill CP,Winslet MC,Watson A. Surveillance of Barrett's columnar-lined oesophagus in the UK: endoscopic intervals and frequency of detection of dysplasia. Eur J Gastroenterol Hepatol 2009; 21:636-641.
18. Congedo E, Aceto P, Petrucci R, Mascia A, Gualtieri E, De Cosmo G. Preoperative anesthetic evaluation and preparation in patients requiring esophageal surgery for cancer. Rays 2005; 30:341-345.
19. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94:2043-2053.
20. Jeffrey GM, Hickey BE, Hider P. Follow up strategies for patients treated for non-metastatic colorectal cancer. Cochrane library (1). Oxford: update software; 2002.
21. Renehan AG, O'Dwyer ST, Whynes DK. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer. BMJ 2004; 328:81.
22. Wolfsen HC, Crook JE, Krishna M, Achem SR, Devault KR, Bouras EP, et al. Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett's esophagus. Gastroenterology 2008; 135:24-31.
23. Gondrie JJ, Pouw RE, Sondermeijer CM, Peters FP, Curvers WL, Rosmolen WD, et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008; 40:370-379.
24. Gondrie JJ, Pouw RE, Sondermeijer CM, Peters FP, Curvers WL, Rosmolen WD, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008; 40:359-369.
25. Dong LM, Kristal AR, Peters U, Schenk JM, Sanchez CA, Rabinovitch PS, et al. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study. Nutr Cancer 2008; 60:39-48.
26. Leedham S, Jankowski J. The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus - the good, the bad, and the flawed! Am J Gastroenterol 2007; 102:21-23.